drugset / Trial / NCT00004313

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency

NCT00004313

RandomizedDouble-blindTreatment

Summary

OBJECTIVES: I. Determine the efficacy of dehydroepiandrosterone (DHEA), an androgen replacement hormone, for patients with primary adrenal insufficiency (Addison's disease).

Timeline

Start
1995-08
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Dehydroepiandrosterone Other / unclassified